Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 241

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia

Open access
Vanover, Kimberly E., Davis, Robert E., Zhou, Yun, Ye, Weiguo, Brašić, James R., Gapasin, Lorena, Saillard, Jelena, Weingart, Michal, Litman, Robert E., Mates, Sharon, Wong, Dean F. · 2019 · Neuropsychopharmacology

Abstract

Dopamine D 2 receptor occupancy (D 2 RO) is a key feature of all currently approved antipsychotic medications. However, antipsychotic efficacy associated with high D 2 RO is often limited by side effects such as motor disturbances and hyperprolactinemia. Lumateperone (ITI-007) is a first-in-class selective and simultaneous modulator of serotonin, dopamine and glutamate in development for the treatment of schizophrenia and other disorders. The primary objective of the present study was to determine D 2 RO at plasma steady state of 60 mg ITI-007, a dose that previously demonstrated antipsychotic efficacy in a controlled trial, administered orally open-label once daily in the morning for two weeks in patients with schizophrenia ( N = 10) and after at least a two-week washout period from standard of care antipsychotics. D 2 RO was determined using positron emission tomography with 11 C-raclopride as the radiotracer. Mean peak dorsal striatal D 2 RO was 39% at 60 mg ITI-007 occurring 1 h post-dose. Lumateperone was well-tolerated with a favorable safety profile in this study. There were no clinically significant changes in vital signs, ECGs, or clinical chemistry laboratory values, including prolactin levels. There were no adverse event reports of akathisia or other extrapyramidal motor side effects; mean scores on motor function scales indicated no motor disturbances with lumateperone treatment. This level of occupancy is lower than most other antipsychotic drugs at their efficacious doses and likely contributes to the favorable safety and tolerability profile of lumateperone with reduced risk for movement disorders and hyperprolactinemia. If approved, lumateperone may provide a new and safe treatment option for individuals living with schizophrenia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41386-018-0251-1

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 241

Metadata

Authors
Vanover, K. E., Davis, R. E., Zhou, Y., Ye, W., Brašić, J. R., Gapasin, L., Saillard, J., Weingart, M., Litman, R. E., Mates, S., & Wong, D. F.
Venue
Neuropsychopharmacology
Published
2018-10-26
Volume
44
Issue
3
Pages
598-605
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W2898434904
Cited by
241
References
6
FWCI
33.29
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. https://app.cochat.ai/papers/10.1038/s41386-018-0251-1
The paper
Vanover, K. E., Davis, R. E., Zhou, Y., Ye, W., Brašić, J. R., Gapasin, L., Saillard, J., Weingart, M., Litman, R. E., Mates, S., & Wong, D. F. (2019). Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. Neuropsychopharmacology. https://doi.org/10.1038/s41386-018-0251-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.